Very nice QTRLY, progress on ROW, re submitting of NNZ-2591 for multiple neurodevelopmental disorders and • $36.8 million cash at 31 December 2021 – well funded to execute NNZ-2591 trials and
foundational work for Phase 3 across all indications.
What's NOT to Like? Yet we get some crazy constant selling of a few shares, pushing down the SP as she starts to run.
it is very frustrating to watch.
Ann: Q4 2021 quarterly activity and cash flow report, page-7
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.81 |
Change
0.060(0.44%) |
Mkt cap ! $1.765B | |||
| Open | High | Low | Value | Volume |
| $13.85 | $14.08 | $13.46 | $6.963M | 507.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3724 | $13.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.84 | 2087 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |